Lifileucel Hits 50% Response Rate in Hard-to-Treat Sarcomas, All Responses Ongoing
IOVA has more than doubled off its 52-week low of $1.76.
Summary
A pilot trial of one-time lifileucel monotherapy in refractory UPS and DDLPS produced a 50% confirmed objective response rate among the first eight evaluable patients, with all four partial responses still ongoing at 6+, 26+, 40+, and 46+ weeks as of the September 9 cutoff. That compares with under 5% ORR for current second-line options in these sarcomas, where median progression-free survival runs about 2-3 months. The FDA already granted fast track designation for lifileucel in advanced UPS and DDLPS in Q2 2026, and Iovance says it is rapidly enrolling the SARATOGA registrational Phase 2 study to support two new approvals. This is a pipeline expansion story layered on top of a commercial business that just raised FY2026 revenue guidance to $410-$420 million on Amtagvi strength. The data are early — eight patients, physician-assessed, pilot-stage — so the real test is SARATOGA's independent-review response rate.
At the time of this announcement, IOVA was trading at $14.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $1.76 to $15.37. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.